P04233 (HG2A_HUMAN) Homo sapiens (Human)
HLA class II histocompatibility antigen gamma chain UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
Available Structures
23 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Cryo-EM structure of human invariant chain in complex with HLA-DQ |
Heteromer P01909; P01920; | 100 | 3×NAG; | |||
| CRYSTAL STRUCTURE OF MHC CLASS II ASSOCIATED P41 II FRAGMENT IN COMPLEX WITH CATHEPSIN L |
Heteromer P07711; | 100 | 1×NAG; | |||
| Cryo-EM structure of human invariant chain in complex with HLA-DR15 |
Heteromer P01903; P01911; | 100 | ||||
| Crystal Structure of HLA-DR1 with CLIP102-120 |
Heteromer P01903; P01911; | 100 | 2×GOL; 1×FMT; | |||
| HLA-DR1 with CLIP102-120(M107W) |
Heteromer P01903; P01911; | 93.33 | ||||
| MHC-II dynamics are maintained in HLA-DR allotypes to ensure catalyzed peptide exchange |
Heteromer A0A4E9DJJ3; P01903; | 100 | 6×EDO; | |||
| Crystal structure of murine class II MHC I-Ab in complex with a human CLIP peptide |
Heteromer P14434; P14483; | 100 | 2×NAG; | |||
| HLA-DR1 with covalently linked CLIP106-120 in reversed orientation |
Heteromer P01903; P01911; | 100 | 2×GOL; | |||
| HLA-DR1 with covalently linked CLIP106-120 in canonical orientation |
Heteromer P01903; P01911; | 100.0 | 4×GOL; | |||
| Crystal Structure of HLA-DR1 with CLIP106-120, flipped peptide orientation |
Heteromer P01903; P01911; | 100 | ||||
| Crystal Structure of HLA-DR1 with CLIP106-120, canonical peptide orientation |
Heteromer P01903; P01911; | 100 | ||||
| THE STRUCTURE OF AN INTERMEDIATE IN CLASS II MHC MATURATION: CLIP BOUND TO HLA-DR3 |
Heteromer P01903; P01911; | 100 | 2×NAG; | |||
| Structure of LAG3 bound to the MHC class II molecule I-A(b) |
Heteromer P14434; P14483; Q61790; | 100 | 4×NAG; | |||
| Structure of LAG3 loop1 deletion bound to the MHC class II molecule I-A(b) |
Heteromer P14434; P14483; Q61790; | 100 | 4×NAG; | |||
| MHC-II dynamics are maintained in HLA-DR allotypes to ensure catalyzed peptide exchange |
Heteromer A0A1V1IGJ9; P01903; | 100 | 9×EDO; 1×FLC; | |||
| F54C HLA-DR1 bound with CLIP peptide |
Heteromer P01903; P01911; | 100 | ||||
| HLA-DR1 bound with CLIP peptide |
Heteromer P01903; P01911; | 100 | ||||
| Crystal structure of HLA-DQ2.5-CLIP1 at 2.73 resolution |
Heteromer P01909; Q5Y7D3; | 100 | ||||
| MHC-II dynamics are maintained in HLA-DR allotypes to ensure catalyzed peptide exchange |
Heteromer D7RIG5; P01903; | 100 | 9×EDO; | |||
| Crystal structure of HLA-DQ2.5-CLIP2 |
Heteromer P01909; Q5Y7D3; | 100 | ||||
| Engineered peptide-specific binder in complex with HLA-DR1/CLIP |
Heteromer D7RIG0; P01903; Q48898; | 100 | 3×NAG; | |||
| HLA-DR ANTIGENS ASSOCIATED INVARIANT CHAIN | homo-3-mer | 100 | ||||
| NMR structure of P41icf, a potent inhibitor of human cathepsin L | monomer | 100 | ||||
3 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8vsp.1.I | monomer | 0.66 | 100.00 | |||
| 1iie.1.A | homo-3-mer | 0.66 | 100.00 | |||
| 8d6u.1.A | monomer | 0.56 | 40.79 | |||
7 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 8vsp.1.I | monomer | 0.68 | 100.00 | |||
| Isoform 2 | 1iie.1.A | homo-3-mer | 0.61 | 100.00 | |||
| Isoform 3 | 8vsp.1.I | monomer | 0.64 | 96.05 | |||
| Isoform 4 | 8vsp.1.I | monomer | 0.67 | 100.00 | |||
| Isoform 4 | 8d6u.1.A | monomer | 0.56 | 40.79 | |||
| Isoform 5 | 8vsp.1.I | monomer | 0.67 | 100.00 | |||
| Isoform 5 | 1iie.1.A | homo-3-mer | 0.61 | 100.00 | |||